91 results on '"Goto, Yasushi"'
Search Results
2. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial
3. Rapid Response to Lenvatinib and Disease Flare Following Discontinuation in a Patient with Thymic Carcinoma Harboring KIT exon 11 Mutation: A Case Report
4. Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
5. O7-3 Phase II study of brigatinib in patients with TKI-naive ROS1-rearranged non-small cell lung cancer (NSCLC): Barossa study
6. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)
7. MO55-5 Impact of tumor genomic alterations on development of cancer cachexia in patients with advanced non-small cell lung cancer
8. MO1-6 Steroid-resistant and refractory irAEs requiring additional immunosuppressants to steroids in advanced NSCLC patients
9. MO26-1 Needs for cancer information in patients with rare cancers: Analysis of the questionnaire from the participants in “Meet the Expert on Rare Cancer”
10. MO35-3 Comparison of clinical outcomes between 1st-line osimertinib, 1G/2G EGFR-TKIs followed by osimertinib and without osimertinib
11. MO35-5 Long-term efficacy and safety from the CROWN study in Japanese patients with ALK+ advanced non-small cell lung cancer
12. MO3-2 Influence of durvalumab consolidation on pneumonitis after chemoradiotherapy for unresectable non-small cell lung cancer
13. Patient-centred, self-funding dose optimisation trials as a route to reduce toxicity, lower cost and improve access to cancer therapy
14. Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC
15. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
16. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy
17. First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN
18. Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
19. Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer
20. Effectiveness and safety of atezolizumab monotherapy in previously treated Japanese patients with unresectable advanced or recurrent non-small cell lung cancer: A multicenter, prospective, observational study (J-TAIL)
21. Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019
22. Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies
23. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
24. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer
25. Machine learning-based exceptional response prediction of nivolumab monotherapy with circulating microRNAs in non-small cell lung cancer
26. Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series study
27. Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients
28. Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC
29. Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients
30. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
31. MO4-3 Adverse events of sequential tyrosine kinase inhibitor following immune checkpoint inhibitor in advanced NSCLC patients
32. P37-1 Liquid biopsy for the detection of the resistant mutation to ROS1 and RET inhibitors: A case series study
33. MO1-6 Characteristics of the tissue obtained in biopsy affecting the success rate of NGS testing in advanced NSCLC patients
34. P62-2 Association of survival and tumor marker value fluctuation during CRT in patients with unresectable stage III NSCLC
35. MO11-1 Efficacy of durvalumab after chemoradiotherapy with daily low-dose carboplatin for unresectable locally advanced NSCLC
36. P78-2 Automatic quantification analysis of amrubicin and amrubicinol using LC-MS/MS
37. MO39-4 An association between p16/MTAP status and the efficacy of cisplatin-plus-pemetrexed or nivolumab treatment of MPM
38. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor
39. O13-1 Phase II study of brigatinib in ROS1-positive non-small cell lung cancer patients previously treated with crizotinib
40. Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy
41. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis
42. Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
43. Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)
44. Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer
45. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer
46. Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
47. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC
48. Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma
49. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
50. Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.